Galectin Therapeutics, Inc. (GALT), on Tuesday, announced additional data from the NAVIGATE trial showing a significant 68.1% reduction in the incidence of new varices in U.S. patients treated with belapectin.
Belapectin, a galectin-3 inhibitor, is being developed for the treatment of Metabolic Dysfunction-Associated SteatoHepatitis or MASH cirrhosis and portal hypertension.
In the U.S. cohort of the trial, the incidence of new varices was significantly lower in the belapectin group compared to placebo, showing promising potential for the drug in treating patients with this chronic liver condition.
These results provide further evidence of belapectin's potential in preventing disease progression in MASH cirrhosis, where currently no FDA-approved therapies exist.
Galectin plans to continue analyzing the data, including results from patients who completed 36 months of treatment, with additional updates expected in the first quarter of 2025.
Joel Lewis, CEO of Galectin Therapeutics, stated, "The 68% reduction in new varices from the NAVIGATE trial highlights belapectin's potential as an important treatment for MASH cirrhosis and portal hypertension, underscoring the need for new therapies to address this pressing medical issue."
Currently, GALT is trading at $1.47 up by 4.25%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.